Your browser doesn't support javascript.
loading
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine.
Basu, Amrita; Albert, Gabriella K; Awshah, Sabrina; Datta, Jashodeep; Kodumudi, Krithika N; Gallen, Corey; Beyer, Amber; Smalley, Keiran S M; Rodriguez, Paulo C; Duckett, Derek R; Forsyth, Peter A; Soyano, Aixa; Koski, Gary K; Lima Barros Costa, Ricardo; Han, Heather; Soliman, Hatem; Lee, Marie Catherine; Kalinski, Pawel; Czerniecki, Brian J.
Afiliación
  • Basu A; Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Albert GK; Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Awshah S; Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Datta J; Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
  • Kodumudi KN; Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Gallen C; Department of Oncological Sciences, University of South Florida, Tampa, Florida.
  • Beyer A; Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Smalley KSM; Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Rodriguez PC; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Duckett DR; Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Forsyth PA; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Soyano A; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Koski GK; Department of NeuroOncology and the NeuroOncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Lima Barros Costa R; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Han H; Department of Biological Sciences, Kent State University, Kent, Ohio.
  • Soliman H; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Lee MC; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Kalinski P; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Czerniecki BJ; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Cancer Immunol Res ; 10(1): 108-125, 2022 01.
Article en En | MEDLINE | ID: mdl-34785506
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Linfocitos T CD4-Positivos / Antígenos de Histocompatibilidad Clase II / Vacunas contra el Cáncer / Receptor ErbB-3 Tipo de estudio: Diagnostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Immunol Res Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Linfocitos T CD4-Positivos / Antígenos de Histocompatibilidad Clase II / Vacunas contra el Cáncer / Receptor ErbB-3 Tipo de estudio: Diagnostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Immunol Res Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos